ReviewFrontiers in immunology2023
Insights into monkeypox pathophysiology, global prevalence, clinical manifestation and treatments.
Review in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.
- The impact of immunosuppression on the mortality and hospitalization of Monkeypox: a systematic review and meta-analysis of the 2022 outbreak.Virology journal · 2024Pooled it
- A comprehensive overview of monkeypox virus disease.Tropical medicine and health · 2026Review
- Mpox Outbreaks Beyond Historically Endemic Regions: A Clinical Review of Vaccination Strategies and Public Health Challenges.Dermatology (Basel, Switzerland) · 2026Review
- Optimal Specimens and Lesions for Mpox Diagnosis Using Real-Time PCR, South Korea.Emerging infectious diseases · 2026Article
- The Emerging Threat of Monkeypox: An Updated Overview.Viruses · 2026Review
- Epidemiological profile and transmission of mpox in the Kamituga health zone of South Kivu, Democratic Republic of Congo: a cross-sectional prospective study.BMC infectious diseases · 2025Article
- Mpox: Global epidemic situation and countermeasures.Virulence · 2025Review
- Best practice of gastrointestinal endoscopy during Mpox upsurge: an Indonesian Society for Digestive Endoscopy recommendation.Clinical endoscopy · 2025Review
- Monkeypox: a re-emergent virus with global health implications - a comprehensive review.Tropical diseases, travel medicine and vaccines · 2025Review
- Current status of next-generation vaccines against mpox virus: a scoping review.Frontiers in pharmacology · 2025Review
- CRISPR-based strategies for sample-to-answer monkeypox detection: current status and emerging opportunities.Nanotechnology · 2024Review
- Mpox in sports: A comprehensive framework for anticipatory planning and risk mitigation in football based on lessons from COVID-19.Biology of sport · 2024Review
- Article
- Monkeypox Virus (MPXV) Infection: A Review.Infectious disorders drug targets · 2024Review
- Advancements in monkeypox vaccines development: a critical review of emerging technologies.Frontiers in immunology · 2024Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
On 23rd July 2022, the World Health Organization (WHO) recognized the ongoing monkeypox outbreak as a public medical crisis. Monkeypox virus (MPV), the etiological agent of monkeypox, is a zoonotic, linear, double-stranded DNA virus. In 1970, the Democratic Republic of the Congo reported the first case of MPV infection. Human-to-human transmission can happen through sexual contact, inhaled droplets, or skin-to-skin contact. Once inoculated, the viruses multiply rapidly and spread into the bloodstream to cause viremia, which then affect multiple organs, including the skin, gastrointestinal tract, genitals, lungs, and liver. By September 9, 2022, more than 57,000 cases had been reported in 103 locations, especially in Europe and the United States. Infected patients are characterized by physical symptoms such as red rash, fatigue, backache, muscle aches, headache, and fever. A variety of medical strategies are available for orthopoxviruses, including monkeypox. Monkeypox prevention following the smallpox vaccine has shown up to 85% efficacy, and several antiviral drugs, such as Cidofovir and Brincidofovir, may slow the viral spread. In this article, we review the origin, pathophysiology, global epidemiology, clinical manifestation, and possible treatments of MPV to prevent the propagation of the virus and provide cues to generate specific drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.